Brief: Verona Pharma Announces Ensifentrine Meets Primary And Key Secondary Endpoints In Phase 3 ENHANCE-1 Trial For COPD
20/12/2022 07:02
Dec 20 (Reuters) - Verona Pharma Plc I9SAy.F :
* VERONA PHARMA ANNOUNCES ENSIFENTRINE MEETS PRIMARY AND KEY
SECONDARY ENDPOINTS IN PHASE 3 ENHANCE-1 TRIAL FOR COPD
* ENSIFENTRINE WAS WELL TOLERATED OVER 24 AND 48 WEEKS
* NDA SUBMISSION PLANNED FOR 1H 2023
Source text for Eikon: ID:nGNX2HC9v1
Further company coverage: I9SAy.F
((Reuters.Brief@thomsonreuters.com;))
Recent news on Verona Pharma
See all newsBrief: Acquisition Of Verona By Msd Approved By The High Court Of Justice Of England And Wales
Brief: Shareholders Of Verona Pharma Approve Proposed Acquisition By Merck
US corporate debt market returns in force after market holiday
Merck to cut jobs and costs as demand for Gardasil in China remains weak (updated)
Merck to cut jobs and costs as demand for Gardasil in China remains weak